Neuromelanin activates proinflammatory microglia through a caspase-8-dependent mechanism

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Viceconte, Nikenza ^a,b,c   Burguillos, Miguel A ^d   Herrera, Antonio J ^a,b   De Pablos, Rocío M ^a,b   Joseph, Bertrand ^c   Venero, José L ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

caspase 3; caspase 8; cytokines; microglia; neuroinflammation; Parkinson's disease

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD14 ANTIGEN; NEUROMELANIN; NITRITE; PATTERN RECOGNITION RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 2; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, HUMAN; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CYTOKINE; LIPOPOLYSACCHARIDE; MELANIN; NITRIC OXIDE; NOD1 PROTEIN, HUMAN; NOD2 PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BV2 CELL; CELL ACTIVATION; CELL LINE; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MESENCEPHALON; MICROGLIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; BRAIN; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TRANSFORMED CELL LINE;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APOPTOSIS; BRAIN; CASPASE 3; CASPASE 8; CELL LINE, TRANSFORMED; CYTOKINES; LIPOPOLYSACCHARIDES; MELANINS; MICE; MICE, INBRED C57BL; MICROGLIA; NITRIC OXIDE; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84924905621     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0228-x     Document Type: Article

References (44)

1. Venero JL, Burguillos MA, Joseph B. Caspases playing in the field of neuroinflammation: old and new players. Dev Neurosci. 2013;35(2-3):88-101.
2. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5(11):897-907.
3. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27(48):6194-206.
4. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471(7338):363-7.
5. Hyman BT, Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci. 2012;13(6):395-406.
6. Sola S, Aranha MM, Rodrigues CM. Driving apoptosis-relevant proteins toward neural differentiation. Mol Neurobiol. 2012;46(2):316-31.
7. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, et al. Caspase signalling controls microglia activation and neurotoxicity. Nature. 2011;472(7343):319-24.
8. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000;23(10 Suppl):S8-19.
9. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382-97.
10. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007;208(1):1-25.
11. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60(8):1059-64.
12. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005;58(6):963-7.
13. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol. 2007;205(2):295-312.
14. Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci. 2013;70(22):4259-73.
15. Venero JL, Burguillos MA, Brundin P, Joseph B. The executioners sing a new song: killer caspases activate microglia. Cell Death Differ. 2011;18(11):1679-91.
16. Koutsilieri E, Lutz MB, Scheller C. Autoimmunity, dendritic cells and relevance for Parkinson's disease. J Neural Transm. 2013;120(1):75-81.
17. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. Activation of microglia by human neuromelanin is NF-κB-dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J. 2003;17(3):500-2.
18. Zecca L, Wilms H, Geick S, Claasen JH, Brandenburg LO, Holzknecht C, et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 2008;116(1):47-55.
19. Zhang W, Zecca L, Wilson B, Ren HW, Wang YJ, Wang XM, et al. Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front Biosci (Elite Ed). 2013;5:1-11.
20. Ishikawa A, Takahashi H. Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J Neurol. 1998;245(11 Suppl 3):4-9.
21. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999;46(4):598-605.
22. Karlsson O, Lindquist NG. Melanin affinity and its possible role in neurodegeneration. J Neural Transm. 2013;120(12):1623-30.
23. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79(1-2):195-200.
24. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 1988;76(6):550-7.
25. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S210-2.
26. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37(3):510-8.
27. Barnum CJ, Tansey MG. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res. 2010;184:113-32.
28. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979-80.
29. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol. 2003;54(5):599-604.
30. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain. 2005;128(11):2665-74.
31. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, et al. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol. 2007;114(4):419-24.
32. Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DK, Blackie J, et al. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol. 2009;217(2):297-301.
33. Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology. 2006;67(7 Suppl 2):S8-11.
34. Zucca FA, Giaveri G, Gallorini M, Albertini A, Toscani M, Pezzoli G, et al. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res. 2004;17(6):610-7.
35. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res. 2003;5(1-2):35-44.
36. Zecca L, Mecacci C, Seraglia R, Parati E. The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta. 1992;1138(1):6-10.
37. Shima T, Sarna T, Swartz HM, Stroppolo A, Gerbasi R, Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med. 1997;23(1):110-9.
38. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009;29(43):13435-44.
39. Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43(11):3063-70.
40. Neniskyte U, Brown GC. Analysis of microglial production of reactive oxygen and nitrogen species. Methods Mol Biol. 2013;1041:103-11.
41. Letiembre M, Hao W, Liu Y, Walter S, Mihaljevic I, Rivest S, et al. Innate immune receptor expression in normal brain aging. Neuroscience. 2007;146(1):248-54.
42. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev. 2009;59(2):278-92.
43. Fernando P, Megeney LA. Is caspase-dependent apoptosis only cell differentiation taken to the extreme? FASEB J. 2007;21(1):8-17.
44. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76(2):77-98.